Pediatric Atopic Dermatitis

In this video, Raj Chovatiya, MD, PhD, discussed continued updates in the use of topical ruxolitinib in pediatric patients with atopic dermatitis.

The FDA has accepted the supplemental new drug application for Zoryve cream 0.05% to treat mild to moderate atopic dermatitis in children aged 2 to 5 years, according to a press release from the manufacturer.

Emma Guttman-Yassky, MD, PhD, lives her life in dichotomy. She’s a dermatologist and an immunologist; a researcher and a department chair; and her medical and research experience transcends the globe, from North America to Europe.

Year-long ruxolitinib cream 1.5% treatment among children aged 2 to 11 years with extensive moderate to severe atopic dermatitis is safe, according to results presented at the Revolutionizing Atopic Dermatitis Conference.

Both methotrexate and cyclosporin are efficacious in the treatment of severe pediatric atopic dermatitis, but methotrexate showed higher rates of sustained treatment response, according to a study.